IMMU-37. VEMURAFENIB ENHANCES THE CYTOTOXICITY OF NY-ESO-1 TCR ENGINEERED T-CELLS FOR BRAF MUTANT BRAIN TUMORS

INTRODUCTION: Missense BRAF mutations are found in a significant portion of pediatric brain tumors, leading to constitutive MAPK pathway activation. By combining immunotherapy with BRAF targeted therapies like vemurafenib, an opportunity might exist to mitigate innate cellular immune escape mechanis...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Neuro Oncol
Main Authors: Bethel, Jacob, Aliche, Julian, Orpilla, Joey, Soto, Horacio, Everson, Richard, Davidson, Tom, Wang, Anthony, Liau, Linda, Prins, Robert
Formato: Artigo
Idioma:Inglês
Publicado em: Oxford University Press 2018
Assuntos:
Abstracts
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6216357/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/noy148.540
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados